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In two recent articles in Science Translational Medicine and Nature Biotechnology, Saito et al. (2010) identify
a molecular signature of acute myeloid leukemia (AML) stem cells and demonstrate that quiescent AML stem
cells become sensitized to chemotherapy after G-CSF stimulation.Acute myeloid leukemia (AML) leukemia
stem cells (LSCs) are defined as malignant
CD34+CD38 cells that can self-renew
and can selectively give rise to serially
transplantable AML in immunodeficient
mice. Like normal hematopoietic stem
cells (HSCs), AML LSCs exist in both
cycling and noncycling (quiescent) states.
Quiescent LSCs have been shown to
reside primarily in bone marrow niches,
where they periodically enter the cell cycle
and give rise to more differentiated leu-
kemic blasts. Whereas traditional chemo-
therapy kills rapidly dividing leukemic
blasts (Figure 1A), quiescent LSCs, shown
in many studies to be highly resistant to
chemotherapy, evade treatment and give
rise to disease relapse. The development
of therapeutic strategies to target quies-
cent, chemotherapy-resistant LSCs has
therefore been a significant thrust of
recent leukemia research.
Because LSCs subvert many of the
pathways that regulate normal HSC main-
tenance, a critical challenge has been
to find effective LSC-directed therapy
that spares normal HSC function. Current
LSC-eradication strategies have largely
focused on targeting aberrant LSC dif-
ferentiation (Geron et al., 2008; Wernig
et al., 2008), LSC self-renewal (Abrahams-
son et al., 2009), or overexpressed
LSC cell-surface proteins. For example,
CD123 (Jin et al., 2009) was recently iden-
tified as a promising molecular target
that is highly expressed in AML LSCsbut dispensable for normal HSC function.
In their Science Translational Medicine
paper, the Ishikawa group adds to this
work by identifying potential AML LSC
targets with the use of microarray profiling
(Saito et al., 2010a). Molecular signatures
of HSC and LSC populations in a mouse
model of chronic myelogenous leukemia
were recently reported (Forsberg et al.,
2010); however, in their work, Saito and
colleagues profiled human HSC and
AML LSC samples and validated pro-
tein expression of candidate genes in
quiescent AML LSC subpopulations.
Notably, Saito and colleagues report that
CD32, CD25, WT1, and HCK were selec-
tively expressed by quiescent LSCs but
were not required for maintaining normal
hematopoiesis (Saito et al., 2010a). In their
Nature Biotechnology report, the group
employed an elegant strategy for target-
ing AML LSCs. The authors found that
G-CSF treatment stimulated quiescent
LSCs to enter the cell cycle, which caused
them to become sensitized to traditional
chemotherapy (Saito et al., 2010b)
(Figure 1B).
Saito and colleagues used two inde-
pendent microarray platforms to establish
a molecular signature uniquely expressed
by primary human AML LSCs. Genes that
were found by both arrays to be highly
expressed in LSCs but to have minimal
expression in HSCs were selected for
quantitative PCR validation on the basis
of functional categories (membraneproteins, kinases, etc.) and were then
further validated with the use of flow
cytometry and immunofluorescence. The
authors then examined expression of
their candidate genes in quiescent LSCs
in vivo. On the basis of in situ analysis of
human xenografted mouse bone marrow,
the authors identified WTI and HCK as
genes specifically expressed in Ki67
LSCs residing in the endosteal niche.
WTI was previously proposed as an LSC
target gene when a knockin reporter-
gene strategy demonstrated that it is ex-
pressed in 40% of LSCs after transfor-
mation with AML1-ETO or BCR-ABL but
not in normal HSCs (Hosen et al., 2007).
HCK, a member of the Src family of tyro-
sine kinases, is normally expressed on
mature myeloid cells and interferes with
Flt-3 signaling but has not previously
been implicated in quiescent AML LSCs.
Through FACS analysis, Saito et al. also
uncovered upregulation of CD32, CD25,
CD18, and CD93 in LSCs compared with
normal HSCs. Notably, CD32 and CD25
are cell-surface receptors that are nor-
mally expressed on B and T cells but
were here found to be overexpressed in
53% of primary AML LSCs. Sorted
CD25+ AML LSCs could also transplant
disease in immunodeficient mice. CD32
expression was less clearly associated
with transplantable LSCs. Some patient
CD32+ AML cells transplanted disease,
whereas others did not, suggesting
that expression of this marker is
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Figure 1. Quiescent AML LSCs Engraft the Bone Marrow of
Immunodeficient Mice
Quiescent AML cells (blue) are enriched in the periosteal region (light-yellow area),
stain Ki67, and slowly differentiate into cycling blasts (red) that fill the central zone
of the marrow and stain Ki67+. Conventional chemotherapeutic agents, including
Ara-C, target and kill rapidly cycling cells by inducing apoptosis (A) but are not
effective against the quiescent LSCs. In contrast, G-CSF and other cytokines can
stimulate quiescent LSCs to cycle and differentiate and increase the sensitivity of
LSCs to conventional chemotherapeutic agents such as Ara-C (B).
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Previewsheterogeneous among
AML LSCs from different
patients. Importantly, nor-
mal human cord-blood
samples depleted of CD32+
or CD25+ cells retained
multilineage hematopoietic
engraftment capacity in
immunocompromised mice,
suggesting that CD32-
or CD25-directed therapy
would be unlikely to affect
normal hematopoiesis.
In parallel with their
molecular analysis of AML
LSCs, Saito and colleagues
also tested whether quies-
cent endosteal AML LSCs
could be cleared by con-
ventional chemotherapeutic
agents after cell-cycle stim-
ulation. Using xenografted
AML samples, they found
that whereas Ara-C treat-
ment targeted S-phase
AML cells and enriched for
quiescent bone marrowLSCs, G-CSF treatment stimulated the
LSCs to cycle and significantly reduced
the levels of quiescent LSCs. The authors
then tested whether cycling LSCs would
be more susceptible to chemotherapy.
Ara-C treatment after induction therapy
with G-CSF led to massive apoptosis
and clearance of endosteal niche LSCs.
Importantly, LSCs treated with both
G-CSF and Ara-C were also significantly
impaired in their capacity to transplant
AML to secondary recipients. However,
as a cautionary note, the survival of
G-CSF- and Ara-C-treated mice was
diminished as a result of treatment-related
toxicity. Also, although the authors found
that normal HSCs were resistant to apo-
ptosis induced by combined G-CSF and
Ara-C treatment, it will be important to
also evaluate HSC function such as long-
term repopulation and self-renewal to
ensure that combined Ara-C and G-CSF
treatment does not significantly deplete
normal quiescent HSCs. Finally, although
Saito et al. provide convincing evidence
that combined G-CSF and Ara-C treat-
ment effectively clears endosteal niche
LSCs, it is important to consider that
quiescent LSCs may reside in other
niches, such as the perivascular niche(Kiel et al., 2005), and that these LSCs
may not be effectively targeted by this
approach. It would be interesting to eval-
uate to what extent AML LSCs occupy
other niches and whether combined
G-CSF and Ara-C treatment could effec-
tively clear these niches of quiescent
AML cells as well.
The recent articles from Saito et al.
highlight the role of quiescent LSCs in
promoting AML relapse after chemo-
therapy and suggest that G-CSF may aid
in therapeutic targeting of quiescent
LSCs in vivo. Although there is little clin-
ical data for how combined G-CSF and
Ara-C treatment might affect AML LSCs
specifically, data from a number of
randomized clinical trials have shown
mixed results from the use of G-CSF
induction chemotherapy in treating AML;
some groups report improvements in
complete remission and disease-free
survival and others report no significant
improvements. Saito and colleagues
note, however, that G-CSF, and LSC-
directed therapy in general, may have little
immediate effect on bulk disease and
therefore on remission rates. Instead,
these therapies may be most clinically
useful postremission to target residualCell Stem Cell 6, April 2, 2AML LSCs and thereby
diminish relapse rates.
Interestingly, interferon-
a treatment, which can acti-
vate quiescent HSCs
(Essers et al., 2009) and
may help to eradicate
quiescent BCR-ABL-ex-
pressing HSCs in chronic
myeloid leukemia, presents
another line of evidence for
the use of cell-cycle stimu-
lation in treating LSCs.
Thus, strategies aimed at
stimulating cell-cycle entry
of LSCs could be important
potential therapeutic ap-
proaches and should be
examined for other types of
leukemia as well.REFERENCES
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